Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Pegilodecakin |
| Synonyms | |
| Therapy Description |
Pegilodecakin (AM0010) is recombinant human interleukin-10 (IL-10) conjugated with polyethylene glycol (PEG), which may induce anti-tumor immune response (J Clin Oncol 34, 2016 (suppl; abstr 3082), PMID: 31706853, PMID: 31563517). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Pegilodecakin | AM0010|AM-0010 | Pegilodecakin (AM0010) is recombinant human interleukin-10 (IL-10) conjugated with polyethylene glycol (PEG), which may induce anti-tumor immune response (J Clin Oncol 34, 2016 (suppl; abstr 3082), PMID: 31706853, PMID: 31563517). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02009449 | Phase I | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel | A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors | Completed | USA | 0 |